TauRx Passes Enrolment In LMTX Study

News : Singaporean pharmaceuticals company TauRx Therapeutics has enrolled 300 patients in a series of P hase III clinical studies for its LMTX clinical property, the company confirmed in a press release. The studies were designed to assess the potential application of the drug as a means to treat patients suffering from mild to moderate forms of Alzheimer ' s disease, and are being conducted at clinical centres in the US, Australia, Croatia and Poland. The studies will ultimately evaluate the use of the drugs in more than 1,500 patients.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Singapore

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.